Evaluation of the new AI post-trade Globant (GLOB) evaluation in healthcare and payments

Why Globant stocks are attracting investor attention again

Globant (GLOB) is gaining new attention with two new partnerships. One will apply our enterprise AI platform to cancer drug discovery with PharmaMar, and the other will expand our role in global payments integration with Adyen.

For you, as an investor, these movements sit at the intersection of healthcare AI and financial services technology, two areas where large clients often require complex, long-term solutions rather than one-off projects.

Check out our latest analysis for Globant.

Despite new AI partnerships in healthcare and payments, Globant’s stock is in a tough spot, with its 90-day stock return down 34% and its one-year total shareholder return down 62%, suggesting the recent news is arriving against a backdrop of weakening sentiment.

If you like the AI ​​angle behind Globant’s recent moves, it may be worth expanding your search to other opportunities in this space, through 34 AI Small-Cap Stocks.

Globant’s stock price is $44.52, trading at a 55% intrinsic discount and a 63% discount to analysts’ current price targets, so the key question is whether this weakness presents a buying opportunity or whether the market is already reflecting future growth.

Most popular story: 39.3% are underrated

The most widely held theory is that Globant is trading well below its estimated fair value of $73.36, with the gap fixed in long-term cash flow assumptions.

The rapid adoption of AI and generative AI across industries is increasing the complexity of enterprise technology environments and increasing the demand for specialized partners to design, implement, and maintain customized AI solutions. With Globant’s enterprise AI platform, AI Pod subscription model, and recent multi-year partnership wins (OpenAI, AWS, etc.), the company is positioned to capture a larger share of this market, potentially impacting both revenue and long-term profits as more high-value, recurring AI engagements translate in the pipeline.

Read the whole story.

Want to know what needs to happen for that fair value to be maintained? This story relies heavily on accelerating earnings compounding, increasing profit margins, and premium earnings multiples. The exact combination may surprise you.

Result: Fair value $73.36 (undervalued)

Read the full explanation to understand what’s behind the predictions.

However, persistent demand weakness and questions over the scalability of the AI ​​pod model could still weigh on growth expectations and challenge the 39.3% undervaluation narrative.

Find out about the key risks to this Globant story.

Another angle on valuation: Earnings multiples tell a different story

The SWS model projects that Globant is trading at a 54.8% discount to estimated fair value, with a market P/E ratio of 18.7x, above the peer average of 11.2x but below the US IT industry’s 19.4x and fair ratio of 30.3x.

This combination of high peer multiples and low fair ratio benchmarks suggests that although the market is cautious about short-term fundamentals, there is still room for sentiment to change if earnings progress is in line with expectations. A key question for investors is which signals to give more weight to.

See what the numbers say about this price. Please check the rating breakdown.

next step

Not sure if the combination of current bearish sentiment and AI potential really makes sense in your view? Act fast, see the data for yourself, and weigh both sides considering 2 important rewards and 2 important warning signs.

Are you ready to discover more opportunities?

If Globant catches your eye, don’t stop here. Expand your watchlist now. Otherwise, you risk missing out on companies that better match your risk and return preferences.

This article by Simply Wall St is general in nature. We provide commentary using only unbiased methodologies, based on historical data and analyst forecasts, and articles are not intended to be financial advice. This is not a recommendation to buy or sell any stock, and does not take into account your objectives or financial situation. We aim to provide long-term, focused analysis based on fundamental data. Note that our analysis may not factor in the latest announcements or qualitative material from price-sensitive companies. Simply Wall St has no position in any stocks mentioned.

Do you have feedback on this article? Interested in its content? Please contact us directly. Alternatively, email editorial-team@simplywallst.com.